Thinking Proactively About Accessing Target Markets
Watch this insightful panel discussion featuring industry leaders Alexander Natz, PhD, Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE); Brad Martin, Head of Market Access and Trade at Neurotech; Lisa Johnson-Pratt, MD, Senior Vice President and Therapeutic Program Lead at Aspen Neuroscience; and Casper Paardekooper, MSc, Partner at Vintura, part of Cencora. Moderated by Jenna Dale, MBA, Associate Director of Market Access & Commercialization at Cencora, this session will delve into accessing target markets for cell and gene therapies across the American and European landscapes.
Key Insights
In this informative discussion, the panelists share their perspectives on accessing markets for cell and gene therapies and the evolving landscape of market access:
- Progress in Cell and Gene Therapy approvals: The panel highlights the advancements made in the cell and gene therapy sector over the past eight years, including successful launches of CAR-T therapies and other gene therapies.
- Proof of concept in Europe: The panel discusses the successful launch of CAR-T therapies in European markets, noting that logistical challenges have been addressed effectively. The ongoing discussions regarding payer willingness to accept high costs for these therapies and the importance of real-world evidence generation to support reimbursement decisions, is addressed.
- Education and access: The panelists underscore the need for education about the complexities of autologous cell therapies, emphasizing that patients must understand the treatment process, from diagnosis to treatment, and the importance of monitoring and follow-up care.
- Common patient experiences: The panel notes that while the patient journey varies, many common challenges exist across different therapies including the need for advocacy and support services to help patients navigate their treatment journeys, particularly in rare and ultra-rare disease contexts.
- Leveraging digital health technologies: The panel discusses the role of digital health technologies in improving patient access and experience. These technologies can facilitate data collection, monitoring, and communication, ultimately enhancing the patient journey.
Watch the full recording for a comprehensive understanding of the strategies for accessing target markets for cell and gene therapies. Fill out the form below to discover how proactive planning and collaboration can enhance market access and improve patient outcomes in this evolving field.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.